Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16118673 | 0.88 | MEN1 (0.46) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL31075527 | 0.83 | MEN1 (0.41) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL26388800 | 0.82 | KMT2A (0.42) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL14657570 | 0.82 | MEN1 (0.42) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL21064425 | 0.81 | MEN1 (0.40) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL17586314 | 0.81 | MEN1 (0.40) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL20243118 | 0.81 | MEN1 (0.41) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL16118720 | 0.81 | MEN1 (0.41) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL21161662 | 0.81 | MEN1 (0.41) | MEN1MAPK1KMT2AAPLNRDPP8 | |
| SCHEMBL17586309 | 0.81 | MEN1 (0.41) | MEN1MAPK1KMT2AAPLNRDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211119-B1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12570640-B2 | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| EP-3980412-B1 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12319671-B2 | 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2025-06-03 | — | — | US | disclosed |
| US-12227511-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-02-18 | — | — | US | disclosed |
| WO-2024067708-A1 | AMMONIUM OXALATE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PHARMACEUTICAL USE OF SAME | 苏州阿尔脉生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| US-20230391789-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-07 | — | — | US | disclosed |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4048662-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220259188-A1 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3980412-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022051337-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051337-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20210115010-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-22 | — | — | US | disclosed |
| US-10975035-B2 | Bicyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| WO-2020247298-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2019-08-01 | — | — | US | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | MEN1 3559/4885MAPK1 240/4885KMT2A 1633/4885 |
| US-20220259188-A1 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, PARK7, BRSK2 | MEN1 4342/4885MAPK1 260/4885KMT2A 2095/4885 |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-12570640-B2 | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, CLK2 | MEN1 4515/4885MAPK1 339/4885KMT2A 1342/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-20230391789-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | HCCS, PRKAA1, PRKAA2 | MEN1 4398/4885MAPK1 449/4885KMT2A 1017/4885 |
| US-10975035-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | MEN1 2548/4885MAPK1 4411/4885KMT2A 3792/4885 |
| US-12227511-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | HCCS, PRKAA1, PRKAA2 | MEN1 4398/4885MAPK1 449/4885KMT2A 1017/4885 |
| US-12319671-B2 | 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, BRSK2 | MEN1 4342/4885MAPK1 260/4885KMT2A 2095/4885 |
| US-20230303540-A1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | MEN1 4150/4885MAPK1 362/4885KMT2A 736/4885 |
| US-20210115010-A1 | BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | CLK1, MAP3K12, CLK2 | MEN1 4004/4885MAPK1 85/4885KMT2A 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.